# A Study of Orally Administered JNJ-56136379 to Evaluate Safety, Tolerability and Pharmacokinetics After Single Ascending Doses and One Multiple Dose Regimen in Healthy Participants (Part I), and After Multiple Dose Regimens in Participants With Chronic Hepatitis B (Part II)

> **NCT02662712** · PHASE1 · COMPLETED · sponsor: **Janssen Sciences Ireland UC** · enrollment: 87 (actual)

## Conditions studied

- Healthy
- Hepatitis, Chronic

## Interventions

- **DRUG:** JNJ-56136379
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02662712
- **Lead sponsor:** Janssen Sciences Ireland UC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-17
- **Primary completion:** 2018-06-29
- **Final completion:** 2018-06-29
- **Target enrollment:** 87 (ACTUAL)
- **Last updated:** 2025-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02662712

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02662712, "A Study of Orally Administered JNJ-56136379 to Evaluate Safety, Tolerability and Pharmacokinetics After Single Ascending Doses and One Multiple Dose Regimen in Healthy Participants (Part I), and After Multiple Dose Regimens in Participants With Chronic Hepatitis B (Part II)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02662712. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*